Locations:
Search IconSearch
August 16, 2017/Cancer

Complex Liver Resection As a Curative Surgery for HCC: A Case Study

Skilled team provides advanced surgical interventions

17-DDI-3851-Complex-Liver-CQD-Hero

By Federico Aucejo, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Liver resection continues to be a mainstay treatment for patients presenting with primary and secondary liver malignancies. In the case of hepatocellular carcinoma (HCC), liver resection is a curative alternative. However in HCC patients with cirrhosis and portal hypertension, liver transplantation is the standard of care.

Pretransplant locoregional therapy or liver resection are common approaches to keep patients within transplant eligibility. In line with this, organ allocation in HCC patients undergoing transplantation in the setting of severe organ scarcity continues to be challenging, as accurate predictors of posttransplant tumor recurrence are lacking.

At Cleveland Clinic’s Hepato-Biliary Cancer Center, we offer advanced surgical interventions via sophisticated surgical techniques to patients with complex tumors.

Vignette:

The patient is a 77-year-old male diagnosed with a large, central HCC abutting the portal vein bifurcation. After undergoing evaluation at a large, out-of-state tertiary facility, the patient received locoregional therapy but was denied surgery due to his age and advanced disease.

Seeking a surgical option and therefore a second opinion, the patient consulted the multidisciplinary Liver Tumor Clinic at Cleveland Clinic.

A large R0 central hepatectomy was successfully performed and the patient was discharged from the hospital on post-operative Day 7 without complications.

Total vascular control (supra-hepatic and infra-hepatic vena cava, and liver hilum) in preparation for parenchymal transection.

Advertisement

Cross sectional imaging via computed tomography demonstrating a large central liver mass (hepatocellular carcinoma).

Surgical resection bed (histopathology analysis confirmed negative tumor margins).

References

  1. Murali AR, Romero-Marrero C, Aucejo F, Menon KV. Hepatocellular carcinoma: options for diagnosing and managing a deadly disease. Cleve Clin J Med. 2013 Oct; 80:645-53.
  2. Kumar AM, Fredman ET, Coppa C, ElGazzaz G, Aucejo FN, Abdel-Wahab M. Patterns of cancer recurrence in localized resected hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2015 Jun; 14:269-75.
  3. Sasaki K, Firl DJ, Hashimoto K, Fujiki M, Diago-Uso T, Quintini C, Eghtesad B, Fung JJ, Aucejo FN, Miller CM. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis. Lancet Gastroenterol Hepatol. 2017 May S2468-1253: 30106-1.
  4. Agopian VG, Harlander-Locke MP, Ruiz RM, et al. Impact of Pre-transplant Bridging Loco-regional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients from the US Multicenter HCC Transplant Consortium. Ann Surg. 2017 Jun 26. PMID: 28654545

Advertisement

Related Articles

Cancer researchers
December 5, 2024/Cancer/News & Insight
Study Examines Neoantigen Landscapes and Their Role in Immunotherapy Efficacy

Researchers develop first-of-its-kind neoantigen atlas to better understand immunotherapy resistance

Interactive culinary medicine class
November 11, 2024/Cancer/Innovations
Integrative Oncology Improves Outcomes and Quality of Life

Combining mind, body and lifestyle practices in alignment with conventional cancer treatment

Pregnant woman
November 6, 2024/Cancer/News & Insight
Large Retrospective Study Finds Pregnancy Safe Among Young BRCA Carriers

Pregnancy did not appear to increase the risk of recurrence in patients or complications in their children

Young patient with cancer
October 25, 2024/Cancer/News & Insight
Multidisciplinary Care Model Supports Young People with Cancer

Integrated program addresses growing need for comprehensive cancer care among adolescents, young adults and adults under 50 with early onset cancers

Hurthle cell carcinoma
October 24, 2024/Cancer/News & Insight
Researchers Uncover Clues to Treating Rare Thyroid Cancer

Studies find mTOR inhibitor may play key role in treating Hurthle cell carcinoma

DNA
October 10, 2024/Cancer/Research
Blocking YES1 Protein Resensitizes Triple-Negative Breast Cancer to Treatment

Obstructing key protein allows for increased treatment uptake for taxane chemotherapy

Ad